CM3 THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS' COMPLIANCE WITH STATINS

CM4 NONADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR MULTIPLE DISEASE CONDITIONS IN A CALIFORNIA MEDICAID POPULATION
Nichol MB 1 , Knight TK 1 , Priest JL 2 , Wu J 1 , Cantrell CR 2 1 University of Southern California, Los Angeles, CA, USA, 2 GlaxoSmithKline, Research Triangle Park, NC, USA OBJECTIVES: To assess quality of care in selected California Medicaid(Medi-Cal) diseases through evaluation of adherence to clinical practice guidelines(CPG) and medications. METHODS: Eligibility and claims data (2002) (2003) (2004) were used to identify patients with hyperlipidemia(HYPL), hypertension(HYPT), coronary artery disease(CAD), congestive heart failure(CHF), diabetes(DIAB), or depression(DEP). Adherence was assessed using 2004 data. CPG adherence was based on appropriate medication use and adherence to recommended laboratory tests(HbA1c,LDL-C) and eye examinations for diabetes patients. Nonadherence to medications was based on medication possession ratio 0.8. Chi-square tests were conducted to evaluate the association of CPG and medication nonadherence with demographic variables. RESULTS: The proportion of patients not using appropriate medications varied by disease(62% DEP, 43% HYPT, 40% HYPL, 31% CAD, 25% for both DIAB and CHF). Approximately 74% of CHF patients were not using any beta blocker(BB). Younger age ( 65 years;p 0.01), Blacks(vs. Whites;p 0.0001), and Medicaid-only patients(vs. Medicare/Medicaid dually eligible;p 0.0001,non signifi cant for BB) were more likely to lack appropriate medications, with the exception of depression, where older patients and whites were more likely without appropriate medications(all p 0.0001). For diabetes patients, 90% lacked HbA1c test, 84% lacked LDL-C test, and 57% were without an eye exam. Older and dually eligible patients were less adherent with these measures (all p 0.0001). Nonadherence with medications was high (84% DEP, 72% CHF, 69% HYPT, 51% CAD, 48% HYPL, 41% DIAB), with younger age(p 0.05), Blacks(p 0.0001), and Medicaid-only patients(p 0.0001, non signifi cant for BB) more likely nonadherent than comparison subgroups. CONCLU-SIONS: Medi-Cal adherence to CPG and medications varied by condition, but was suboptimal across all diseases. A greater proportion of patients were nonadherent to medication than were not using appropriate medications. Future investigation focused on potential factors infl uencing medication nonadherence(i.e.,poor disease knowledge, cultural beliefs) is recommended. Disease-management programs designed for specifi c diseases, and addressing patient-related characteristics (age, race) along with alterable factors(eligibility), may be most effective for improving adherence.
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DB1 PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
Aagren M g 1 , Thomsen TL 2 , Knudsen VK 3 1 Novo Nordisk Inc, Princeton, NJ, USA, 2 Novo Nordisk A/S, Virum, Denmark, 3 Novo Nordisk A/S, Bagsvaerd, Denmark OBJECTIVES: Type 2 diabetes is a chronic illness that affects more than 17 million Americans, leading to early death as well as to reduced quality of life due to complications such as blindness, renal failure etc. This study was undertaken with the aim of estimating cost-effectiveness of the premix analog insulin, biphasic insulin aspart 30 (BIAsp), when switched from biphasic human insulin (BHI). METHODS: The well validated CORE Diabetes Model was used to project the clinical outcomes based on short-term data (26 weeks) from a Canadian subset of the IMPROVE™ observational study. The cohort (n 310) had a mean age of 64.2 10.96 years and 61.7% are male. In the IMRPOVE™ study, patients were switched from BHI to BIAsp and the main results included a reduction of HbA1c from 8.42 1.61% to 7.84 1.46%, an increase in BMI of 0.28 2.33 kg/m2 and a reduction in major and minor hypoglycemic events by 75% and 33%, respectively. Total direct medical costs (complications treatment costs) were projected, using US unit costs, over patient lifetimes, and future costs and clinical benefi ts discounted at 3% per annum. RESULTS: The short-term benefi ts of switching from BHI to BIasp are projected to lead to an increase in discounted quality-adjusted life expectancy of 0.276 years (4.289 0.094 versus 4.013 0.098). Increased total lifetime costs/patient is $4,936 ($84,776 2,423 versus $79,840 2,545) with BIasp. Combining costs and clinical outcomes result in an incremental cost-effectiveness ratio of $17,859 per quality-adjusted life year (QALYs) gained. CONCLUSIONS: Higher acquisition costs of BIasp are projected to be partly offset by reduced later diabetes-related complications. The net life time cost increase is greatly justifi ed by improved outcomes. The incremental costeffectiveness ratio is well within what is normally considered good value for money in the United States.
DB2
ANTI-HYPERTENSIVE DRUG USE AND RISK OF DEMENTIA IN PATIENTS WITH DIABETES MELLITUS (DM)
Johnson ML 1 , Parikh NM 2 , Kunik M 3 , Schulz P 4 , Chen H 1 , Aparasu R 1 , Yadav R 1 , Morgan R 5 1 University of Houston, Houston, TX, USA, 2 Analysis Group Inc, Boston, MA, USA, 3 Center of Quality of Care and Utilization Studies, Veterans Affairs Medical Center, Houston, TX, USA, 4 Baylor Neurology, Houston, TX, USA, 5 University of Texas, Houston, TX, USA OBJECTIVES: Anti-hypertensive therapy (AHT), especially the drug classes acting on Renin-Angiotensin system (RAS) and Calcium Channel Blockers (CCB), is known to delay the onset of dementia. The aim of this study was to determine whether different AHT drug classes are independent risk factors for dementia in DM patients, who are at increased risk of dementia. METHODS: For the purpose of this retrospective study, we identifi ed a national cohort of US veterans (age 65 years) with incident DM between October 1996 and December, 2000 in the VA records or between January, 1999 and December, 2000 in the VA-Medicare merged data. The presence of hypertension (HT) was also assessed within the same period. The period prevalence for each
